Bellerophon Therapeutics (NASDAQ:BLPH) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research note released on Wednesday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

BLPH stock opened at $0.06 on Wednesday. Bellerophon Therapeutics has a 1-year low of $0.03 and a 1-year high of $11.15. The firm has a market cap of $685,048.00, a P/E ratio of -0.07 and a beta of 0.69. The business’s 50 day moving average is $0.06 and its 200-day moving average is $0.05.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.